International expert consensus on hospital intelligent pharmacy

As the rapid advancements in medical technology and increasing demands for personalized medication, Hospital Intelligent Pharmacy (HIP) integrates artificial intelligence, large-scale health data analytics, the Internet of Things (IoT), and other cutting-edge technologies to optimize end-to-end pharmaceutical supply chain processes, management, and clinical processes. In recent years, regulatory agencies such as the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA), China’s National Medical Products Administration (NMPA), and the U.S. Food and Drug Administration (USFDA) have issued policies to promote intelligent pharmacy development. However, HIP still faces challenges including ambiguous definitions, absence of standardized technical protocols, and incomplete evaluation frameworks. To address these issues, international and domestic academic organizations collaboratively developed the International Expert Consensus on Hospital Intelligent Pharmacy. This consensus clarifies HIP’s definition, core components, and systematic framework, providing scientific guidance for standardized implementation and clinical application of intelligent pharmacy in hospitals. Utilizing a Delphi method process, expert opinions will be collected, analyzed, and refined. The current consensus defines HIP’s scope and principles, outlining a framework with 10 components: intelligent drug supply chain management, drug dispensing, prescription review, pharmacovigilance, medication therapy management, therapeutic drug monitoring, telepharmacy services, pharmacy administration, science popularization, and clinical trials. Future directions focus on 5 key areas: AI-augmented pharmacist competency development, advancing pharmaceutical scientific research, fostering intelligent pharmaceutical publications and journals, addressing ethical and legal challenges, and promoting international harmonization in pharmacy. The consensus offers critical references and exploratory pathways for HIP’s global advancement.

Authors

Institutions

Publication Details

Journal
Intelligent Pharmacy
Published
2025-06-18
DOI
https://doi.org/10.1016/j.ipha.2025.06.001
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International expert consensus on hospital intelligent pharmacy

Xinan Yue, Y Tang, Yilei Li, Hua Tao et al.
Intelligent Pharmacy
Pharmaceutical Practices and Patient Outcomes
article

International expert consensus on hospital intelligent pharmacy

Xinan Yue, Y Tang, Yilei Li, Hua Tao, Li Cao, J. F. Wu, Zhigang Zhao, Aizong Shen, Alice Hao, Wenshuo Jiang
article en

Abstract

As the rapid advancements in medical technology and increasing demands for personalized medication, Hospital Intelligent Pharmacy (HIP) integrates artificial intelligence, large-scale health data analytics, the Internet of Things (IoT), and other cutting-edge technologies to optimize end-to-end pharmaceutical supply chain processes, management, and clinical processes. In recent years, regulatory agencies such as the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA), China’s National Medical Products Administration (NMPA), and the U.S. Food and Drug Administration (USFDA) have issued policies to promote intelligent pharmacy development. However, HIP still faces challenges including ambiguous definitions, absence of standardized technical protocols, and incomplete evaluation frameworks. To address these issues, international and domestic academic organizations collaboratively developed the International Expert Consensus on Hospital Intelligent Pharmacy. This consensus clarifies HIP’s definition, core components, and systematic framework, providing scientific guidance for standardized implementation and clinical application of intelligent pharmacy in hospitals. Utilizing a Delphi method process, expert opinions will be collected, analyzed, and refined. The current consensus defines HIP’s scope and principles, outlining a framework with 10 components: intelligent drug supply chain management, drug dispensing, prescription review, pharmacovigilance, medication therapy management, therapeutic drug monitoring, telepharmacy services, pharmacy administration, science popularization, and clinical trials. Future directions focus on 5 key areas: AI-augmented pharmacist competency development, advancing pharmaceutical scientific research, fostering intelligent pharmaceutical publications and journals, addressing ethical and legal challenges, and promoting international harmonization in pharmacy. The consensus offers critical references and exploratory pathways for HIP’s global advancement.

Intelligent PharmacyVol. 3(6)
University of Science and Technology of China (CN), Sun Yat-sen University (CN), Capital Medical University (CN), Chinese Academy of Sciences (CN), Beijing United Family Hospital (CN), Beijing Tian Tan Hospital (CN), Sun Yat-sen Memorial Hospital (CN), Nanfang Hospital (CN), Institute of Automation (CN), Mount Carmel St. Ann's (US), Southern Medical University (CN)
Openalex Percentile: Top 84%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.